Key points from article :
Verséa Ophthalmics to distribute Celularity’s BIOVANCE and BIOVANCE 3L Ocular products to support the treatment of ocular surface disease and ocular surgical applications.
BIOVANCE and BIOVANCE 3L Ocular are intended for use as a biological membrane covering that provides an extracellular matrix.
BIOVANCE 3L Ocular consists of three layers of an amniotic membrane that supports treatment of advanced ocular surface disease.
As a barrier membrane, BIOVANCE 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries.
Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures.
“Verséa Ophthalmics has the channel expertise in eye care necessary to reach physicians and to provide patients in need access to our innovative biomaterial technology,” - Robert Hariri, Celularity’s CEO.
“Our agreement to offer a decellularized, ringless, advanced wound healing option to drive forward innovation for ocular surface diseases,” -Rob Sambursky, President of Verséa Ophthalmics.
